Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792385 | 0.93 | CPB2 (0.37) | CPB2L3MBTL1TSHRCYP2D6ALDH1A1 | |
| SCHEMBL774206 | 0.93 | CPB2 (0.37) | CPB2L3MBTL1TSHRCYP2D6ALDH1A1 | |
| SCHEMBL774745 | 0.93 | CPB2 (0.37) | CPB2L3MBTL1TSHRCYP2D6ALDH1A1 | |
| SCHEMBL8084596 | 0.87 | TSHR (0.57) | TSHRCYP2D6ALDH1A1NPSR1ZDHHC7 | |
| SCHEMBL15287645 | 0.82 | NAAA (0.46) | TSHRNPSR1ZDHHC7 | |
| SCHEMBL28825960 | 0.82 | TSHR (0.52) | L3MBTL1TSHRCYP2D6ALDH1A1NPSR1 | |
| SCHEMBL30304082 | 0.82 | NAAA (0.46) | TSHRNPSR1ZDHHC7 | |
| SCHEMBL30304015 | 0.82 | NAAA (0.46) | TSHRNPSR1ZDHHC7 | |
| SCHEMBL30801437 | 0.80 | ZDHHC7 (0.54) | TSHRZDHHC7LMNA | |
| SCHEMBL32683934 | 0.80 | L3MBTL1 (0.43) | L3MBTL1TSHRCYP2D6ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-8623897-B2 | Methods and compositions for treatment of diabetes and dyslipidemia | KAREUS THERAPEUTICS, SA (CH) | 2014-01-07 | — | — | US | disclosed |
| EP-2618824-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | Kareus Therapeutics SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012040177-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | LIPC, PNLIP, LIPA | CPB2 1453/4885L3MBTL1 3604/4885TSHR 2566/4885 |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | GPR119, FFAR1, INSR | CPB2 2854/4885L3MBTL1 874/4885TSHR 102/4885 |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | DHCR7, INSR, GPR119 | CPB2 1572/4885L3MBTL1 473/4885TSHR 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.